Ligand Pharmaceuticals extends credit facility maturity to Sept 2028, sets minimum EBITDA at $55M

LIGAND PHARMACEUTICALS INC

Third Amendment to Credit Agreement dated Sep 12, 2025 extends maturity to September 12, 2028.
New minimum consolidated EBITDA covenant: not less than $55 million for trailing four-quarter periods.
Amendment modifies credit agreement originally dated Oct 12, 2023, with all Lenders consenting.
Borrower reaffirmed obligations and Guarantors reaffirmed guarantees under the agreement.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.